A groundbreaking step in the fight against HPV-induced cancers!

  • TheraVectys has enrolled the first patient in a Phase I/IIa clinical trial for Lenti-HPV-07, a therapeutic vaccine for HPV-induced cancers.
  • The trial will include 36 patients and aims to evaluate the vaccine’s safety, immunogenicity, and preliminary efficacy.
  • Lenti-HPV-07 has shown promising preclinical results, including complete tumor elimination in 100% of subjects.
  • The vaccine is based on a lentiviral vector technology platform developed over nearly 20 years.
  • The trial will assess two groups: patients with recurrent/metastatic cancers and newly diagnosed, treatment-naïve patients.

TheraVectys, a biotechnology company specializing in lentiviral vector-based vaccines, has announced the enrollment of the first patient in a Phase I/IIa clinical trial for its therapeutic vaccine, Lenti-HPV-07. This vaccine targets human papillomavirus (HPV)-induced cancers, specifically oropharyngeal and cervical cancers. The trial will involve 36 patients and aims to evaluate the vaccine’s safety, immunogenicity, and preliminary efficacy. Preliminary results on safety and immune response are expected a few months after the last injection for the first group of patients.nnThe Lenti-HPV-07 vaccine is built on a lentiviral vector technology platform that has been in development for nearly two decades. Previous preclinical studies have shown that a single injection of the vaccine can induce a robust immune response against HPV16 and HPV18, leading to the complete elimination of HPV-induced tumors in all subjects, regardless of tumor size. The vaccine also demonstrated a long-lasting immune memory and effective tumor microenvironment remodeling.nnThe clinical trial will consist of two patient groups: Group A will include patients with recurrent or metastatic cancers who have not responded to multiple treatments, while Group B will consist of newly diagnosed, treatment-naïve patients. Each group will receive different dosing regimens of the vaccine, and safety will be closely monitored throughout the trial.nnTheraVectys has a strong safety record, having previously completed a Phase I trial for a therapeutic HIV-1 vaccine without notable side effects. The ongoing trial for Lenti-HPV-07 uses a non-integrative lentiviral vector, further enhancing its safety profile. The company aims to demonstrate the vaccine’s synergistic effects with existing treatments, such as anti-PD1 therapies, which could significantly improve treatment outcomes for patients with HPV-related cancers.nnThe inclusion of the first patient marks a significant milestone for TheraVectys, reflecting over two years of preparation and collaboration with regulatory authorities and clinical partners. With HPV being a leading cause of cervical and oropharyngeal cancers, the development of effective immunotherapies like Lenti-HPV-07 could revolutionize treatment options and improve patient outcomes.·

Factuality Level: 8
Factuality Justification: The article provides detailed information about a clinical trial for a new vaccine, including its methodology, expected outcomes, and previous research findings. While it is generally factual and informative, it contains some promotional language and may present the vaccine’s efficacy in a somewhat optimistic light without sufficient caution regarding preliminary results.·
Noise Level: 8
Noise Justification: The article provides detailed information about a clinical trial for a new vaccine, including its methodology, expected outcomes, and previous research supporting its efficacy. It stays on topic, supports claims with evidence from preclinical studies, and discusses the implications of the research. However, it lacks critical analysis of the broader implications or potential risks associated with the treatment.·
Private Companies: TheraVectys
Key People: Christian Bréchot (Medical Director), Pierre Charneau (head of the Pasteur-TheraVectys Joint Laboratory and founder), Estelle Besson (Director of Clinical Operations), Jean Chalopin (Chairman), Laleh Majlessi (Director of Research in Immunology)

Financial Relevance: Yes
Financial Markets Impacted: Yes
Financial Rating Justification: The article discusses TheraVectys, a biotechnology company involved in developing a vaccine for HPV-induced cancers, which is a financial topic as it relates to the biotech industry and potential market impacts. The enrollment of the first patient in a clinical trial could influence investor sentiment and stock prices for TheraVectys and similar companies in the biotech sector, particularly those focused on cancer therapies.·
Presence Of Extreme Event: No
Nature Of Extreme Event: No
Impact Rating Of The Extreme Event: No
Extreme Rating Justification: The article discusses the enrollment of the first patient in a clinical trial for a vaccine against HPV-induced cancers, which is not an extreme event.·
Move Size: No market move size mentioned.
Sector: Healthcare
Direction: Up
Magnitude: Large
Affected Instruments: Stocks

Reported publicly: www.businesswire.com